At the news
? BULLISHIMPACT 7/10 6-K filed Mar 30, 2026 at 06:35 ET
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype in patients aged 12 and older. The approval is based on SWIFT-1 and SWIFT-2 phase III trials showing significant reductions in asthma exacerbations, with 58% and 48% lower annualized exacerbation rates versus placebo, respectively.
- Exdensur approved in China for severe asthma with eosinophilic phenotype in patients aged 12+
- Approval based on SWIFT-1 and SWIFT-2 phase III trials demonstrating 58% and 48% reduction in annualized exacerbation rates versus placebo
- Exdensur is the first and only ultra-long-acting biologic in China with twice-yearly dosing for this indication
- More than 2 million people in China suffer from severe asthma
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access